Mazdutide
Mazdutide, also called IBI362, is an investigational lab-made peptide drug that switches on two metabolic hormone receptors at once. It is being studied in clinical trials as a once-weekly injection for weight management and metabolic health.
At a glance
- Metabolic support
- subcutaneous
- Not yet audited here; the reference library calls it human data available
- 2.5 mg per Peptide Dosages. See the source
- 10 mg in 3 mL
How much to draw
Full calculator →Opened on 2.5 mg, the figure Peptide Dosages reports for Mazdutide, and a 10 mg vial in 3 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Mazdutide or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 2.5-5 mg | Once weeklyTitrate over weeks per tolerance | subcutaneous | Peptide Dosages -What it saysHideEducational protocol, mirrors clinical-trial gradual titration. [Source: Peptide Dosages] |
- Once weeklyTitrate over weeks per tolerance
- subcutaneous
- Peptide Dosages -
What it saysHide
Educational protocol, mirrors clinical-trial gradual titration. [Source: Peptide Dosages]
- 10 mg vial · 10 mg vial + 3.0 mL bacteriostatic water (~3.33 mg/mL). Draw 3.0 mL BAC water, inject slowly down the vial wall, swirl gently (do not shake), refrigerate at 2-8 C protected from light.
We have not published an audit on Mazdutide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
It acts on two receptors at the same time, one tied to appetite and blood sugar control and the other to energy use and liver metabolism. Researchers link this to the GLP-1 receptor, where activation reduces appetite, slows stomach emptying, raises glucose-dependent insulin release and lowers glucagon when glucose is high, and to the glucagon receptor, which affects energy expenditure, amino acid metabolism, fat handling and liver metabolism. Because of that pairing it is not simply another GLP-1 drug, and the effect depends on the combined receptor pharmacology, the dose studied and the group of patients enrolled. Preclinical and mechanistic findings on liver, fat tissue, glucose handling and body weight still need confirmation in human trials.
Dual agonism of GLP-1 and glucagon receptors; studied for appetite regulation, energy expenditure, and metabolic effects.
Reported side effects
Not ruled out: reported tolerability concerns overlap with other incretin-based treatments, especially gastrointestinal adverse events. Safety interpretation also covers low blood sugar in diabetes settings, gallbladder and pancreas considerations, and monitoring needs. In people with type 2 diabetes, changes in appetite, stomach emptying or glucose may call for clinician-supervised monitoring, particularly alongside insulin or drugs that make the body release insulin, which raise the risk of low blood sugar. Discontinuation because of side effects is noted as a relevant endpoint when reading obesity trials.
What gets monitored
The page notes that people with type 2 diabetes taking mazdutide may require clinician-supervised monitoring of appetite, gastric emptying, and glucose levels, particularly when combined with insulin or insulin secretagogues. Clinical trial endpoints that serve as monitoring markers include glycated hemoglobin (HbA1c), fasting plasma glucose, body weight, waist circumference, blood pressure, lipids, liver-related measures, and adverse event rates including hypoglycemia. (reported by Peptide Dosages)
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
Cagrilintide / Retatrutide is a combination of cagrilintide, an amylin analog, and retatrutide, a triple GLP-1, GIP and glucagon agonist, sold pre-blended in one vial or as separate vials. It is discussed for weight management, and no clinical trial has tested the two together.
Cagrilintide / Tirzepatide is a combination of cagrilintide, an amylin analog, and tirzepatide, a dual GIP and GLP-1 agonist, each given once weekly from its own vial. It is discussed for weight management, with one study in obese rats and no human trial of the two together.
CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, given once weekly. It has been studied for weight management in people in Phase 3 trials and is not FDA-approved as of June 2026.
Retatrutide is an investigational once-weekly injectable that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is being studied for weight and metabolic outcomes in adults with obesity, type 2 diabetes and fatty liver disease.
Semaglutide is a lab-made copy of GLP-1, a gut hormone that helps the body manage hunger and blood sugar. It is among the most heavily studied weight-loss and diabetes medicines, with trial programmes covering more than 45,000 participants.
Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.